Advertisement

NHS to pilot 'game-changing' blood test that could detect 50 types of cancer

Sir Simon Stevens, the NHS chief executive, said the blood test could help 'thousands more people to get successful treatment' - Aaron Chown/ PA
Sir Simon Stevens, the NHS chief executive, said the blood test could help 'thousands more people to get successful treatment' - Aaron Chown/ PA

A "game-changing" blood test that could detect more than 50 types of cancer is to be introduced by the NHS, the head of the health service has said.

Charities said the move could "save lives on a vast scale" by detecting potentially lethal disease years before symptoms emerged.

The new checks, which use a simple blood test, will be piloted with 165,000 patients in a deal struck by NHS England, funded by a US diagnostics company.

Research has found the tests – which identify molecular changes – can detect types of disease that are difficult to diagnose early, such as ovarian, pancreatic and oesophageal cancers.

Participants aged between 50 and 79 will be asked to have annual blood tests for three years. If the programme shows that the "Gallieri" test, developed by US-based company Grail, works as well as trials suggest, it will be rolled out to become routinely available.

In England, around half of cancers are currently diagnosed at an early stage, with targets to increase this to three quarters by 2028. Patients who have their condition diagnosed at stage one typically have up to 10 times the chance of surviving compared with those whose condition is found at stage four.

Sir Simon Stevens, the NHS chief executive, said that while cancer survival is now at a record high more then 1,000 people are diagnosed daily.

He said: "Early detection – particularly for hard to treat conditions like ovarian and pancreatic cancer – has the potential to save many lives. This promising blood test could therefore be a game-changer in cancer care, helping thousands more people to get successful treatment."

Britain is lagging in international league tables for cancer survival, largely because so many cases are spotted so late.

Experts are fearful that the Covid pandemic has worsened this crisis, increasing the numbers who have not come forward to have worrying symptoms checked.

People will be identified through NHS records and approached to take part in the trials, which are due to start next year. Anyone with a positive test will be referred to the NHS for further checks. Another 25,000 people with possible cancer symptoms will also be offered testing to speed up their diagnosis after being referred to hospital in the normal way.

The results of the trials are expected by 2023 and, if outcomes are positive, then they would be expanded to involve around one million participants across 2024 and 2025.

Matt Hancock, the Health Secretary, said: "We are building a world-leading diagnostics industry in the UK – not just for coronavirus but for other diseases too.

"This exciting and groundbreaking new blood test from Grail will give us another tool to give more people the very best chance of survival, demonstrating how the UK continues to lead the way in using the latest innovative treatments to help patients."

Michelle Mitchell, Cancer Research UK's chief executive, said earlier diagnosis of cancer was the single biggest opportunity to save lives from the disease.

"All too often, people are diagnosed with cancer at a late stage when their disease is more difficult to treat," she added. "This is a human tragedy, not just in terms of lives lost, but it also means more expensive treatments, hospital stays and monitoring.

"If we can turn this on its head and find cancer at its earliest stages when it's easier to treat, not only will we be able to save lives on a vast scale, but we may be able to save our NHS millions of pounds."

Lord David Prior, the chairman of NHS England, said: "This collaboration between the NHS and Grail offers the chance for a wide range of cancers to be diagnosed much earlier and could fundamentally change the outlook for people with cancer."